Prisys Biotechnologies Co., Ltd.

Prisys Biotechnologies Co., Ltd. (also known as Shanghai Puling Biotechnology) operates as a preclinical contract research organization (CRO) focused on translational research using non-human primate (NHP) models. The company has developed an industrial-scale research platform featuring proprietary technologies such as AI-based 3D behavioral quantification, real-time MRI-guided convection-enhanced delivery (CED) for neurological drug administration, and clinical-grade multi-modal imaging. By integrating clinical-identical infrastructure with specialized NHP research laboratories, Prisys provides a translational toolkit designed to bridge the gap between preclinical development and human clinical trials, focusing on areas like neuroscience, immunology, and metabolic disease research.

Prisys serves a global client base of pharmaceutical companies, research institutions, and clinical organizations, supporting drug discovery with services including efficacy evaluation, safety assessment, pharmacokinetics, and biodistribution studies. The company’s research facilities are AAALAC-accredited, ensuring high standards for animal care and research ethics. By providing human-relevant preclinical data, Prisys helps partners de-risk drug development programs, accelerate IND submissions, and improve therapeutic outcomes for complex human diseases. Their collaborative model includes co-development opportunities, allowing researchers access to specialized disease models and innovative delivery systems to advance their therapeutic pipelines.